Founded in 2014 as a wholly owned subsidiary of Kelun Group and affiliated company of Kelun-Biotech, KLUS Pharma is committed to the discovery and development of advanced therapeutic biotechnologies. Our top priority is to address the needs of patients suffering from cancers, cardiovascular diseases, autoimmune diseases, and other severe disorders due to lack of effective treatments. Utilizing our innovative technology platforms of monoclonal antibodies, bi-specific antibodies, and Antibody-Drug Conjugates (ADCs), we have advanced multiple biologic programs into the clinical stage to treat these debilitating conditions. KLUS Pharma has streamlined antibody discovery and engineering capabilities, which enable a seamless transition from target discovery to product development. Our team of industry experts in immuno-oncology, immunology, and cardiology, can rapidly advance biological drug candidates from bench to market. KLUS Pharma has identified and assessed dozens of therapeutic targets and is currently conducting preclinical and clinical studies for more than 10 antibody-based therapeutics.